Retrospective, multi-centre, open-label study on the use of alemtuzumab for relapsing–remitting multiple sclerosis in clinical practice: A 4-year follow-up
Introduction: The efficacy and safety of alemtuzumab for patients with relapsing–remitting multiple sclerosis (RRMS) have been demonstrated in clinical trials. However, due to the limitations of these studies, it is important to assess the effects of the drug in clinical practice. The purpose of thi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Neurology Perspectives |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667049625000109 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|